Peter J Kertes1, Ivan J Galic2, Mark Greve3, R Geoff Williams4, Emmanouil Rampakakis5, Andrea Scarino6, Tom Sheidow7. 1. The John and Liz Tory Eye Centre, Sunnybrook Health Sciences Center, and University of Toronto, Toronto, Canada. Electronic address: Peter.Kertes@sunnybrook.ca. 2. Montreal Retina Institute, and McGill University, Montreal, Canada. 3. Alberta Retina Consultants, and University of Alberta, Edmonton, Canada. 4. Calgary Retina Consultants, and University of Calgary, Calgary, Canada. 5. JSS Medical Research, Saint-Laurent, Canada. 6. Novartis Pharmaceuticals Canada, Dorval, Canada. 7. Ivey Eye Institute, and Western University, London, Canada.
Abstract
PURPOSE: To compare the efficacy of ranibizumab using a treat-and-extend (T&E) regimen with monthly dosing in treatment-naive patients with neovascular age-related macular degeneration (nAMD). DESIGN: Prospective, randomized, open-label, multicenter, noninferiority, postauthorization study. PARTICIPANTS: Treatment-naive patients with choroidal neovascularization secondary to AMD. METHODS:Patients with nAMD were randomized 1:1 to receive intravitreal ranibizumab at a dose of 0.5 mg in either a T&E or monthly dosing regimen. The noninferiority of T&E compared with the monthly dosing regimen was to be shown using a margin of 5 letters in best-corrected visual acuity (BCVA) improvement. MAIN OUTCOME MEASURES: Mean change in BCVA in Early Treatment Diabetic Retinopathy Study letters from baseline to month 12. RESULTS: Baseline and 12-month visual acuity data are available for 526 patients (T&E, n = 268; monthly, n = 258). At baseline, mean age was 78.8 years (standard deviation [SD], 7.8 years), 60.3% were women, and 94.3% were white. No significant between-group baseline differences were observed. The primary outcome of noninferiority regarding visual acuity was met with mean BCVA improvement of 8.4 letters (SD, 11.9 letters) and 6.0 letters (SD, 11.9 letters; P = 0.017) in the T&E and monthly regimens, respectively, with a between-group mean difference of 2.38 letters (95% confidence interval, 0.32-4.45 letters). Per protocol, a secondary analysis was performed to test for superiority of number of injections received up to month 12. This analysis demonstrated significantly fewer injections with T&E versus monthly dosing (9.4 and 11.8 injections, respectively), with a mean difference of -2.46 injections (95% confidence interval, -2.68 to -2.23 injections). CONCLUSIONS: The 12-month results of this 2-year study demonstrated that regarding visual outcomes, the T&E regimen was noninferior to a monthly dosing regimen. Similar visual outcomes in the T&E group as in the monthly dosing group were achieved with significantly fewer injections.
RCT Entities:
PURPOSE: To compare the efficacy of ranibizumab using a treat-and-extend (T&E) regimen with monthly dosing in treatment-naive patients with neovascular age-related macular degeneration (nAMD). DESIGN: Prospective, randomized, open-label, multicenter, noninferiority, postauthorization study. PARTICIPANTS: Treatment-naive patients with choroidal neovascularization secondary to AMD. METHODS:Patients with nAMD were randomized 1:1 to receive intravitreal ranibizumab at a dose of 0.5 mg in either a T&E or monthly dosing regimen. The noninferiority of T&E compared with the monthly dosing regimen was to be shown using a margin of 5 letters in best-corrected visual acuity (BCVA) improvement. MAIN OUTCOME MEASURES: Mean change in BCVA in Early Treatment Diabetic Retinopathy Study letters from baseline to month 12. RESULTS: Baseline and 12-month visual acuity data are available for 526 patients (T&E, n = 268; monthly, n = 258). At baseline, mean age was 78.8 years (standard deviation [SD], 7.8 years), 60.3% were women, and 94.3% were white. No significant between-group baseline differences were observed. The primary outcome of noninferiority regarding visual acuity was met with mean BCVA improvement of 8.4 letters (SD, 11.9 letters) and 6.0 letters (SD, 11.9 letters; P = 0.017) in the T&E and monthly regimens, respectively, with a between-group mean difference of 2.38 letters (95% confidence interval, 0.32-4.45 letters). Per protocol, a secondary analysis was performed to test for superiority of number of injections received up to month 12. This analysis demonstrated significantly fewer injections with T&E versus monthly dosing (9.4 and 11.8 injections, respectively), with a mean difference of -2.46 injections (95% confidence interval, -2.68 to -2.23 injections). CONCLUSIONS: The 12-month results of this 2-year study demonstrated that regarding visual outcomes, the T&E regimen was noninferior to a monthly dosing regimen. Similar visual outcomes in the T&E group as in the monthly dosing group were achieved with significantly fewer injections.
Authors: Jason Hsu; Samir N Patel; Jeremy D Wolfe; Chirag P Shah; Eric Chen; Thomas L Jenkins; Turner D Wibbelsman; Anthony Obeid; Mikel Mikhail; Sunir J Garg; Allen C Ho; Allen Chiang; Marc J Spirn; James F Vander Journal: JAMA Ophthalmol Date: 2020-05-01 Impact factor: 7.389
Authors: Peter K Kaiser; Charles C Wykoff; Rishi P Singh; Arshad M Khanani; Diana V Do; Hersh Patel; Nikhil Patel Journal: Retina Date: 2021-08-01 Impact factor: 3.975
Authors: Peter J Kertes; Ivan J Galic; Mark Greve; Geoff Williams; Jason Baker; Marcel Lahaie; Tom Sheidow Journal: JAMA Ophthalmol Date: 2020-03-01 Impact factor: 7.389
Authors: Winfried Amoaku; Clare Bailey; Louise Downey; Richard P Gale; Faruque Ghanchi; Robin Hamilton; Sajjad Mahmood; Geeta Menon; Jenny Nosek; Ian Pearce; Yit Yang Journal: Clin Ophthalmol Date: 2020-05-15
Authors: Federico Ricci; Francesco Bandello; Pierluigi Navarra; Giovanni Staurenghi; Michael Stumpp; Marco Zarbin Journal: Int J Mol Sci Date: 2020-11-03 Impact factor: 5.923